Sign In
Buy SMMT
$14.25
-0.0300 (-0.210%)
At Close: Jun 23, 2026
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet
09:05am, Monday, 22'nd Jun 2026
Summit Therapeutics is a highly volatile, single-asset company with a binary outcome. SMMT exhibits unusually concentrated ownership and heightened short interest, creating conditions for a short sque
First Look: U.S.-Iran Peace Deal Lifts Global Stocks, SpaceX Shines
07:36am, Monday, 15'th Jun 2026
Stock News Global markets rally on Iran peace deal: Equities surged worldwide and oil prices dropped after the U.S. and Iran reached a tentative agreement to en
Summit Therapeutics Announces Proposed Public Offering of Common Stock
04:47pm, Tuesday, 09'th Jun 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
03:08pm, Monday, 08'th Jun 2026
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
09:30am, Sunday, 07'th Jun 2026
After years of lagging the market, healthcare may be taking on a new role in investor portfolios.
The Era of the One-Size-Fits-All Cancer Drug Is Ending
05:30am, Saturday, 06'th Jun 2026
Investors have bet new drugs can topple Merck's Keytruda, but the evidence so far points to something smaller.
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
04:30pm, Thursday, 04'th Jun 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
01:01pm, Thursday, 04'th Jun 2026
Summit Therapeutics (SMMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress Transcript
What's Going On With Summit Therapeutics Stock On Monday?
10:56am, Monday, 01'st Jun 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) stock is down on Monday following the recent announcement regarding the clinical trial results of ivonescimab on Sunday.
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet
10:56am, Monday, 01'st Jun 2026
The consensus price target hints at a 67.1% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
06:34am, Monday, 01'st Jun 2026
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced
01:45pm, Sunday, 31'st May 2026
Biotech companies have always licensed programs, but never so many from one region in particular.
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and spons
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by
